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Cold-chain requirements, limited stockpiling potential and the lack of potent immune 
responses are major challenges of parenterally formulated influenza vaccines. 
Decreased cold chain dependence and stockpiling can be achieved if vaccines 
are formulated in a dry state using suitable excipients and drying technologies. 
Furthermore, having the vaccine in a dry state enables the development of non-
parenteral patient friendly dosage forms: microneedles for transdermal administration, 
tablets for oral administration, and powders for epidermal, nasal or pulmonary 
administration. Moreover, these administration routes have the potential to elicit an 
improved immune response. This review highlights the rationale for the development 
of dried influenza vaccines, as well as processes used for the drying and stabilization 
of influenza vaccines; it also compares the immunogenicity of dried influenza vaccines 
administered via non-invasive routes with that of parenterally administered influenza 
vaccines. Finally, it discusses unmet needs, challenges and future developments in 
the field of dried influenza vaccines.






Parenteral vaccination against influenza is the gold standard for controlling 
dissemination of the disease. Low costs per dosage unit and ease of formulation 
still renders it suitable for mass vaccination programs all over the world. However, 
current seasonal and pandemic influenza vaccines need to be stored and distributed 
at refrigerated temperatures (2–8°C); the so-called cold chain must be applied to 
ensure product stability and prevent antigen degradation. Stabilization of the antigen 
by drying with suitable excipients would greatly improve storage stability. The 
restricted molecular mobility in the dry state may preserve the conformational and 
structural integrity of the antigen which could make the cold chain superfluous[1,2]. In 
addition, improved storage stability can greatly enhance stockpile potential in case of 
a pandemic outbreak. 
Drying techniques like spray drying[3–5], freeze drying[6–8], spray freeze drying[9–11] 
and air or vacuum drying[12,13] can be used in combination with suitable excipients 
not only to improve antigen stability but also to provide a solid carrier or vesicle 
to reach the desired target site, depending upon the route of administration. The 
currently preferred injection site for influenza vaccination is the deltoid muscle. 
Since muscle tissue has a low number of antigen presenting cells (APCs) and lacks 
major histocompatibility complex (MHC) class II cells, its potential to induce potent 
humoral and cellular immune responses is limited[14]. Further, passive drainage of 
the antigen to lymph nodes might require high antigen doses, thereby posing the 
risk of shortage in case of pandemics. Alternative routes that target areas rich in 
APCs like mucosal surfaces and the skin might be better target sites for influenza 
vaccination. Vaccines could, for example, be in the form of a dry powder with a 
certain particle size, shape and density that targets a specific area in the lungs[15], 
nasal cavity[12] or dermis[9] (pulmonary, nasal and epidermal powder immunization); 
or a film-coated[16] or dissolvable matrix[17] to target the skin (dermal vaccination); or 
a tablet to target the sublingual[18], buccal[19] and gut regions[20] (oral vaccination). 
To be more specific, these alternative forms could target immune cells resident in 
these areas to provide a more potent humoral and cellular immune response than 
currently achieved by conventional parenteral vaccination. The use of new routes 
could lead to reduction of doses, improve the efficacy of the vaccine and make 




presents an overview of the publications found on dry influenza vaccines per route 
of administration expressed as percentage. This review gives an overview of current 
developments in dry influenza vaccines, including their drying techniques and 
various alternative routes of administration. We will compare these formulations with 
standard parenteral influenza vaccines in terms of stability and efficacy. Finally, we 
will share a perspective on these dry influenza vaccines and their possibilities to 
improve current influenza vaccination practices.
Commonly used drying techniques for influenza vaccines
Typical drying processes use convection, conduction or radiation (infrared) as 
methods of heat transfer[21]. Pharmaceuticals such as antigens in influenza vaccine 
formulations are often prone to degradation due to heat, cooling or freezing, as well as 
shear and dehydration stresses caused by the drying process. To prevent degradation 
during the drying process and improve storage stability at room temperature, 
one can use stabilizing excipients like polysaccharides, such as inulin or dextran, 
and disaccharides, such as trehalose[22–24]. During drying hydroxyl groups of the 
saccharides replace the hydrogen bonds of water surrounding the antigen, thereby 
preserving the protein’s three-dimensional structure. Furthermore, upon drying the 
antigen is also stabilized by vitrification when the saccharide forms a glassy matrix 
around the antigen[25–27]. Therefore, one should select a saccharide with a high glass 
prone to degradation due to heat, cooling, or freezing, as well
as sh ar and d hydration stresses caused by the dryi g process.
To prevent degradation during the drying process and improve
storage stability at room temperature, one can use stabilizing
excipients like polysaccharides, such as inulin or dextran, and
disaccharides, such as trehal se [22–24]. During drying hydr xyl
groups of the saccharides replace the hydrogen bonds of water
surrounding the antigen, thereby preserving the protein’s
th ee-dim nsional structure. Furthermore, upon dryi g the anti-
gen is also stabilized by vitrification when the saccharide forms
a glassy matrix around the antigen [25–27]. Therefore, one
should select a saccharide with a high glass transition tempera-
ture (Tg) as the residual moisture can strongly decrease the Tg
because of the plasticizing effects of water. Since antigens in
influenza vaccines are usually given in very low doses (only a
few micrograms), the saccharides can also be used as a bulking
agent. The most frequently used methods for drying influenza
vaccines are spray drying, (spray)freeze drying, and air drying or
vacuum drying. We will therefore discuss these techniques in
the sections below.
Spray drying
Spray drying is a well-established technique to produce dry
powders. In general, a pumpable liquid or solution (also called
the feed material) is atomized into small droplets by a nozzle.
Atomization is the process by which liquid is broken up into
fine droplets (usually in a micrometer range). The droplets
containing the antigen are sprayed under atomization into
the drying-chamber where they come in contact with a stream
of dry hot air, resulting in the evaporation of liquid to form dry
particles [28,29]. The atomization of the liquid, the subsequent
drying of the droplet, and the effect of the outlet temperature
will induce shear, dehydration, and heat stress, respectively,
thereby possibly resulting in degradation and loss of potency
of the antigen. For this reason, stabilizing excipients like (poly)
saccharides are used during the spray drying process [30]. In
most cases, the spray-dried particles are separated from the
stream of air by a cyclone and collected in the attached vial.
However, collection by bag filters or electrostatic precipitation
is also used [31,32]. Often spherically shaped hollow particles
with a shell are obtained, which have a lower density than solid
particles. A spray dried solid particle usually looks like a raisin
due to its wrinkled appearance [33]. Since the size, shape, and
density of a dry particle play an important role in pulmonary,
epidermal, and (to a lesser extent) intranasal (i.n.) dry powder
immunization it is important to understand the factors that
influence these characteristics. The relation between particle
characteristics and administration routes will be discussed
later in this review.
(Spray)freeze drying
While spray drying utilizes heat to dry the desired product,
freeze drying utilizes a partial vacuum to dry the product
while in the frozen state. In general, a liquid formulation con-
taining the solute(s) (e.g. antigen, saccharide, salts, and buffer
components) and a suitable solvent (usually water) is first com-
pletely solidified by freezing. During the freezing of an aqueous
solution, water will start to crystallize into ice crystals that form
a matrix among the remaining solution. Due to the presence of
solutes the remaining liquid water will start to crystallize at
lower temperature due to freezing point depression. Upon
further cooling, more water will crystallize and the remaining
solution will become more concentrated until the glass transi-
t on temp rature of the maximally freeze-concentrated fraction
(Tg’) will be reached and water will no longer crystallize.
Instead, the remaining maximally freeze-concentrated solution
will form a glass [34]. To obtain a product in the glassy state,
cooling should be fast enough to prevent crystallization of the
saccharide. The liquid formulation is usually frozen on the shelf
of the freeze dryer at a temperature of ‒20 to ‒100°C, but can
also be snap frozen outside the freeze dryer, for example in
liquid nitrogen. Snap freezing is also used during spray freeze
drying where the solution is atomized (with a technology simi-
lar to that used in spray drying) after which the formed droplets
are collected and frozen into liquid nitrogen [35] or onto a cold
surface [36]. The drying process is initiated by lowering the
pressure in the chamber of the freeze dryer to a partial vacuum
(microbar range). The drying process consists of two stages,
namely primary and secondary drying. During primary drying,
ice crystals will sublimate from the frozen formulation. During
this process, to prevent crystallization of the saccharide, the
temperature of the frozen solution should not exceed the Tg’.
Once all the ice crystals have been sublimated from the frozen
formul ion, the primary drying process is completed and sec-
ondary drying starts. During secondary drying, water evapo-
rates from the maximally freeze-concentrated fraction, the
pressure in the freeze drying chamber is further lowered
(usually by a factor of 10) and the temperature is gradually
increased. The secondary drying phase is completed when the
desired residual moisture content is achieved to ensure product
stability. With conventional freeze drying, the product consists
of a porous cake, and with spray freeze drying, it consists of
porous spherical particles [37].
Air drying, nitrogen purging, and vacuum drying
More simplistic approaches to achieve a dry vaccine product
are by air drying, nitrogen purging, or vacuum drying. Usually
Figure 1. Publications found on dry influenza vaccines per route of administra-
tion expressed as percentage. Numbers are based on literature found from 2000
to 2015 using Embase and Pubmed.
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transition temperature (Tg) as the residual moisture can strongly decrease the Tg 
because of the plasticizing effects of water. Since antigens in influenza vaccines are 
usually given in very low doses (only a few micrograms), the saccharides can also 
be used as a bulking agent. The most frequently used methods for drying influenza 
vaccines are spray drying, (spray) freeze drying and air drying or vacuum drying. We 
will therefore discuss these techniques in the sections below.
Spray drying
Spray drying is a well-established technique to produce dry powders. In general, 
a pumpable liquid or solution (also called the feed material) is atomized into 
small droplets by a nozzle. Atomization is the process by which liquid is broken 
up into fine droplets (usually in a micrometer range). The droplets containing the 
antigen are sprayed under atomization into the drying-chamber where they come 
in contact with a stream of dry hot air, resulting in the evaporation of liquid to 
form dry particles.[28,29]. The atomization of the liquid, the subsequent drying of 
the droplet and the effect of the outlet temperature will induce shear, dehydration 
and heat stress, respectively, thereby possibly resulting in degradation and loss of 
potency of the antigen. For this reason, stabilizing excipients like (poly)saccharides 
are used during the spray drying process[30]. In most cases the spray dried particles 
are separated from the stream of air by a cyclone and collected in the attached 
vial. However, collection by bag filters or electrostatic precipitation is also used[31,32]. 
Often spherically shaped hollow particles with a shell are obtained, which have a 
lower density than solid particles. A spray dried solid particle usually looks like a 
raisin due to its wrinkled appearance[33]. Since the size, shape and density of a 
dry particle play an important role in pulmonary, epidermal and (to a lesser extent) 
intranasal (i.n.) dry powder immunization, it is important to understand the factors 
that influence these characteristics. The relation between particle characteristics and 
administration routes will be discussed later in this review.
(Spray) Freeze drying
While spray drying utilizes heat to dry the desired product, freeze drying utilizes 
a partial vacuum to dry the product while in the frozen state. In general, a liquid 
formulation containing the solute(s) (e.g. antigen, saccharide, salts and buffer 




freezing. During the freezing of an aqueous solution, water will start to crystallize into 
ice crystals that form a matrix among the remaining solution. Due to the presence 
of solutes the remaining liquid water will start to crystallize at lower temperature 
due to freezing point depression. Upon further cooling, more water will crystallize 
and the remaining solution will become more concentrated until the glass transition 
temperature of the maximally freeze concentrated fraction (Tg¢) will be reached and 
water will no longer crystallize. Instead, the remaining maximally freeze-concentrated 
solution will form a glass[34]. To obtain a product in the glassy state, cooling should 
be fast enough to prevent crystallization of the saccharide. The liquid formulation is 
usually frozen on the shelf of the freeze dryer at a temperature of –20 to –100°C , but 
can also be snap frozen outside the freeze dryer, for example in liquid nitrogen. Snap 
freezing is also used during spray freeze drying where the solution is atomized (with 
a technology similar to that used in spray drying) after which the formed droplets 
are collected and frozen into liquid nitrogen[35] or onto a cold surface[36]. The drying 
process is initiated by lowering the pressure in the chamber of the freeze dryer to a 
partial vacuum (microbar range). The drying process consists of two stages, namely 
primary and secondary drying. During primary drying ice crystals will sublimate 
from the frozen formulation. During this process, to prevent crystallization of the 
saccharide the temperature of the frozen solution should not exceed the Tg¢. Once 
all the ice crystals have been sublimated from the frozen formulation, the primary 
drying process is completed and secondary drying starts. During secondary drying, 
water evaporates from the maximally freeze concentrated fraction; the pressure in 
the freeze drying chamber is further lowered (usually by a factor of 10) and the 
temperature is gradually increased. The secondary drying phase is completed when 
the desired residual moisture content is achieved to ensure product stability. With 
conventional freeze drying the product consists of a porous cake, and with spray 
freeze drying it consists of porous spherical particles[37].
Air drying, nitrogen purging and vacuum drying
More simplistic approaches to achieve a dry vaccine product are by air drying, 
nitrogen purging or vacuum drying. Usually the product is first air dried or dried in 
a stream of inert gas, e.g. nitrogen, and then, if the product needs further drying, it 
is often subjected to a partial vacuum; for this purpose an airtight container like a 




a vacuum pump to apply a partial vacuum. A highly hygroscopic material (like silica 
gel) on the bottom of the desiccator absorbs the evaporated water from the product. 
During these drying processes the formulation remains for a substantial period of 
time (hours) in the rubbery state before it is vitrified. This might be detrimental 
to the antigen for two reasons[38,39]. First, during drying in this state, the solution 
becomes more concentrated while the antigen is not immobilized. This may easily 
cause changes in the three-dimensional structure of the antigen, or aggregation with 
loss of potency as a result. Secondly, the saccharide may crysallize, thereby fully 
losing its stabilizing effects[40]. These drying methods may therefore not be most 
suitable for obtaining a stable dry vaccine formulation. 
Routes of administration
Transdermal dry influenza vaccine delivery
The barrier property of the outermost layer of the skin i.e. stratum corneum (10–
20 µm) protects the body from the surrounding environment and prevents the entry 
of pathogens. On the one hand, the barrier function prevents antigen uptake in 
or through the skin. This explains the need to apply an administration technique 
that penetrates the stratum corneum to obtain adequate antigen delivery. On the 
other hand, the abundance of large numbers of diverse immune cells like epidermal 
Langerhans cells (LC) and dermal dendritic cells (DC) make the skin a highly suitable 
immunological organ for vaccination. Both LC and DC serve as immune responsive 
APCs, which are involved in the up take and presentation of pathogen derived 
antigens to naïve B and T-cells, hence inducing an adaptive immune response[14,41]. 
Epidermal powder immunization as a dry influenza vaccination method 
Dry influenza vaccines can be used for dermal vaccination by ballistic powder 
delivery or epidermal powder immunization (EPI). Elongated tubular devices or 
ballistic injectors like the PowderJect use compressed sterile helium gas to fire the 
dry powder vaccine from a compartment or cassette through a nozzle into the skin. 
These dry powders can be produced by conventional drying methods like spray 
drying, or freeze drying or purging with nitrogen gas, followed by desiccation and 
grinding to achieve the desired particle size. The desired particle size depends on 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the depth of penetration into the (epi)dermis (about 100–500 µm) are particle size, 
density, shape and velocity. Improved designs of epidermal injectors focus mainly on 
creating high uniform particle velocities, which are necessary to ensure deposition of 
the particles within the dermis. Dry powder influenza vaccines suitable for epidermal 
powder delivery are usually dried with polysaccharides or disaccharides to improve 
stability[43,44]. As a result of this drying process, dry powder vaccines most often have 
a low particle density. To compensate for this low density the dry powder particles 
need to be relatively large in size (20–60 µm) and dispersed at high velocities 
(300–1000 m/s) in order to penetrate the skin at the desired depth[42]. However, 
some studies have shown to improve particle density by increasing the solid content 
of the spray freeze dried feed material, and utilize the promotion of particle shrinkage 
by using different excipients[44]. Over the past 15 years, EPI against influenza has 
been investigated in preclinical studies as well as in a clinical study and compared 
with conventional liquid injections.
Chen et al. showed that EPI administration of 25, 5 and 1 µg of whole inactivated 
virus (WIV) to mice induced significantly higher antibody titers than did parenteral 
administration (Table 1)[45]. Furthermore, EPI conferred 100% protection against 
lethal virus for all three doses whereas administration by conventional s.c. injection 
elicited only partial protection: 75% and 62,5 % survival at a dose of 25 µg and 
5 µg respectively, and no survival at a dose of 1 µg[45]. Likewise, in another mice 
study EPI induced higher antibody titers than did liquid vaccine administered 
intramuscularly[46]. However, in monkeys (rhesus macaques) unadjuvanted 
formulations elicited similar antibody titers by both intramuscular and epidermal 
routes[46]. Nonetheless, the co-administration of adjuvant quillaja saponins-21 
(QS-21) with the same influenza vaccine to monkeys by EPI elicited higher antibody 
titers than did only antigen or i.m. administration[46].
Several other adjuvants like CpG oligonucleotide (CpG ODN), cholera toxin (CT), 
cholera toxin b subunit (CTB) and bacterial toxin mutants (LTR72 or LTR63) 
co-administered with trivalent influenza vaccine were found to enhance serum 
antibody titers after EPI in mice[46–50,85].
The mechanisms behind the enhanced immune response elicited by EPI were 




sites to naïve mice[50]. It was found that the depletion of LC caused a significant 
reduction in antibody responses whereas transfer to naïve mice induced robust 
antigen specific antibody responses[50]. These results provided direct evidence that 
LC function as APCs following epidermal powder immunization to evoke an immune 
response.
In a phase 1 clinical trial conducted in healthy adults, EPI with trivalent influenza 
vaccine was shown to elicit strong antibody responses and high seroconversion rates 
that were equivalent or higher than in the i.m. group[9].
The clinical trial and preclinical studies have shown the potential of EPI for 
vaccination against influenza as it produces immune responses similar to or better 
than vaccination via the parenteral route.
Microneedles mediated dry influenza vaccination 
In the last decade, based on the aforementioned immunological properties of 
the skin, dry influenza vaccines delivery by microneedles has been extensively 
investigated. Administration via microneedles is also an attractive alternative to 
conventional hypodermic needles because it is a painless delivery system due to the 
relatively short needle length (about 200–700 µm), which does not reach the nerve 
endings. Different approaches have been used to deliver dry solid influenza vaccines 
using microneedles. One approach is to coat a solution containing the vaccine onto 
the outer surface of non-dissolving microneedles. Non-dissolving microneedles for 
influenza vaccination are usually made of materials such as stainless steel, titanium, 
silicon or glass and manufactured by a chemical etching process, a strong cutting 
laser, or electropolishing[86]. The coating is applied by dipping a small array of 
microneedles into a coating solution and then drying by an air or vacuum drying. A 
coating solution usually consists of a stabilizing saccharide like trehalose to prevent 
the antigen from losing its activity during drying/storage, a viscosity enhancer like 
carboxymethylcellulose (CMC) to eventually obtain a coating of sufficient thickness, 
and a wetting agent or surfactant like poloxamer to reduce the surface tension of the 
coating solution and to ensure uniform coating efficiency (Fig. 2A). 
Each of these excipients has a unique potential to influence the stability of various 




(WIV) virus (A/PR8 H1N1) was coated onto solid microneedles in the absence 
of trehalose in the coating solution[54]. The magnitude of immune response and 
protection against viral challenge elicited by coated microneedles was equivalent to 
i.m. immunization in mice[54]. In addition, 3–10 µg of H3N2 WIV (A/Aichi H3N2) 
delivered to the skin induced a level of immune response similar to that after i.m. 
administration[51]. The need for such high doses of influenza vaccine was hypothesized 
due to the stability issues arising from the sudden phase change of the vaccine from 
a liquid to a dry state[52,55]. Consequently, efforts were made to stabilize influenza 
vaccines coated on microneedles and the stabilization was speculated to play a role 
in dose sparing.
It was found that low dose (0.4 µg) of trehalose stabilized WIV (A/PR8 H1N1) 
administered to mice using microneedles, resulted in better viral protection and 
generation of rapid recall immune responses superior to i.m. formulations at the 
same dose (Table 1)[52,53]. Similarly, a low dose (0.3–2 µg) of stabilized virus-like 
particles (VLPs) (A/PR8 H1N1, A/Vietnam H5N1) coated on microneedles and 
administered to mice showed superior Th1 responses[55], potent recall responses 
and complete protection (100%) as compared to partial protection (≤40%) by 
intramuscularly immunized mice[55–57]. Notably, it has been shown that stabilized 
influenza VLPs could provide complete protection at a threefold lower dose than 
that of unstabilized influenza VLPs[55]. Hence, the stabilization combined with skin 
vaccination using microneedles has potential to elicit strong antibody titers, superior 
Th1 responses and rapid recall immune responses with a low dose. This plays a 
vital role in providing microneedle mediated superior protection. Dose sparing 
could also be achieved by the use of the Nanopatch (NP), a patch with densely 
packed (21,000 microprojections/cm2 compared to ≤321 microprojections/cm2 
of microneedles) coated microprojections of shorter length (110µm compared to 
700µm microneedles) designed to target thousands of skin APCs[60]. Chen et al. 
reported that the commercial trivalent split vaccine (Fluvax®) coated onto NP 
administered to mice is able to elicit comparable protective immune responses 
comparable to those found after administration via the i.m. route, but with a dose 
30 times lower. Moreover, the NP was found to be stable for 6 months at room 
temperature, providing immunogenicity comparable to that of freshly prepared 
patches[60]. Later, the co-delivery of trivalent split influenza vaccine and saponin 




to mice induced IgG antibody and hemagglutination inhibition (HAI) titers that were 
similar in magnitude to conventional i.m. injection (6000 ng of vaccine without 
adjuvant), but with a 900 fold lower dose[62].
The long term stability of coated microneedles is also a critical factor influencing 
the immunogenicity of the vaccine. Kim et al. investigated the influence of storage 
time on the immunogenicity of WIV coated on the microneedles[67]. After 4 weeks 
of storage at room temperature, stabilized microneedles induced high antibody 
titers and protected mice from lethal viral challenge[67]. Mechanistic studies on 
degradation during storage revealed a direct correlation between the degree of time-
dependent phase transformation (crystallization and phase separation) of vaccine 
coating and hemagglutinin (HA) activity[13]. Vaccine coated microneedles stored at 
room temperature for 4 months were found to be phase transformed and poorly 
immunogenic as compared to fresh coated formulations[13]. Further, osmotic stresses 
during drying result in destabilization of WIV indicating the need for viscosity 
enhancers[68,74]. Viscosity enhancers like CMC also seem to play an important role in 
diminishing the surfactant induced phase transformations of the vaccine coating, thus 
preserving antigen stability[74]. Hence, the presence of viscosity enhancer augmented 
vaccine specific systemic immune responses and provided better protection against 
viral challenge[74]. 
The choice of excipients also depends on the nature and type of influenza vaccine. 
Microneedles were coated with H5 influenza HA encoding DNA vaccine using 
a viscosity enhancer and a surfactant. Mice vaccinated with coated microneedles 
elicited higher levels of antibody, HAI titers and a better viral protection than those 
vaccinated with conventional i.m. injection of the similar DNA vaccine, still the 
protection elicited by microneedles was only partial[66]. The partial protection was 
attributed to the viscosity enhancer which diminished the expression efficiency of the 
DNA vaccine, thereby reducing its immunogenicity[66]. Due to the inherent stability 
and viscosity of DNA vaccines, they have also been coated onto microneedles 
without additional excipients like stabilizers or viscosity enhancers. Microneedle 
based skin delivery of HA encoding DNA vaccine (excipient-free coating) induced 
potent humoral, cellular, memory responses and better protection than did i.m. 
immunization[65]. In another study, the co-delivery approach of WIV (A/PR8) and 




immune responses against heterologous influenza strains (pandemic 2009 H1N1)[69]. 
Due to the high viscosity of DNA vaccines, it played a dual role as an immunogen 
and a viscosity enhancer. Furthermore, sugar was incorporated in the formulation to 
stabilize WIV and its HA activity was fully maintained. The co-immunization of DNA 
vaccine together with WIV by microneedles generated both homologous (A/PR8) and 
heterologous (A/California/2009) immune responses in mice comparable to or better 
than i.m. vaccination[69]. 
The long term protective efficacy of different influenza vaccines coated on 
microneedles was investigated by viral challenge several weeks or months after 
vaccination. Microneedle mediated or subcutaneous (s.c.) delivery of WIV in mice 
exhibited similar antibody titers and complete protection against viral challenge 6 
weeks after vaccination[61]. Six months post vaccination, microneedle group had high 
antibody titers and complete viral protection whereas the s.c. group had a 60% 
decline in antibody titers and only partial protection was provided against a lethal 
viral challenge[61]. Likewise, Koutsonanos et al. showed that subunit vaccine (A/
Brisbane H1N1) generated peak antibody levels at week 8 when administered in 
mice by the i.m. route, as compared to week 12 mice immunized by microneedles[63]. 
Both vaccinated groups of mice were fully protected against lethal challenge at 4 
or 12 weeks post immunization. However, at 36 weeks post immunization, 38% 
of the i.m. immunized animals had a significant decline in HAI titers below 40 
(HAI < 40) whereas the microneedle group had HAI titers high enough to confer 
complete protection against lethal challenge (HAI > 40)[63]. Similarly, the protective 
efficacy of stabilized VLPs (A/PR8 H1N1) coated on microneedles was investigated 
by viral challenge fourteen months after a single vaccine dose in mice[71]. Significant 
systemic, mucosal and recall immune responses provided complete protection 
against viral challenge even after such a substantial period of time[71]. These findings 
thus demonstrate that stabilized influenza vaccines delivered by microneedles can 
generate longer lasting immunity and better protection than conventional systemic 
routes.
To assess whether a vaccine formulation could induce a broad protective immunity 
and serve as a proof of concept for a universal flu vaccine, four repeats of a conserved 
part of the M2 protein linked to the toll like receptor-5 (TLR-5) ligand Salmonella 




to mice. A homo and heterosubtypic lethal viral challenge of mouse adapted A/
Philippines (H3N2) and A/PR/8 (H1N1) showed that all the microneedle immunized 
mice survived[75]. Post-challenge lung viral titers of microneedle immunized mice 
were more effectively reduced than those of intramuscularly immunized mice[75]. 
In another study, a patch of microneedles coated with virus-like particles (VLP) 
containing heterologous M2e extracellular domains (M2e5x) of influenza virus 
stabilized with trehalose induced a broad heterosubtypic cross-protection in mice[16]. 
Microneedle immunized mice showed a strong induction of humoral and mucosal 
M2e antibody responses and were better cross-protected than i.m. immunized mice 
against heterosubtypic (H1N1, H3N2 and H5N1) lethal viral challenge. Further, the 
antigenicity and immunogenicity of the M2e5x-VLP were maintained for at least 8 
weeks at room temperature[16]. Microneedle mediated delivery of conserved epitopes 
show promising results and holds a great potential for further development of 
universal flu vaccination. Not only are broad and cross-reactive immune responses 
desired but also an influenza vaccine that is safe and effective for all age groups 
would be preferable.
Children, elderly and immunocompromised patients are more susceptible to 
influenza infection than other individuals. Therefore, the protective efficacy of skin 
based delivery was also investigated in young mice[73]. The microneedle vaccinated 
group showed improved humoral responses, reduced lung viral titres and better 
viral protection after viral challenge than did the i.m. group. These potent humoral 
responses and better survival after challenge were attributed to higher numbers of 
antibody secreting cells and activated germinal center formation[73]. Besides mice, 
guinea pigs were also inserted with microneedles coated with commercial trivalent 
vaccine. Comparable immune titers were observed for both the microneedle and i.m. 
group[70]. 
Another approach uses (water) dissolving microneedles consisting of vaccines 
encapsulated in matrices of polymers like CMC, polyvinylpyrrolidone (PVP), 
polyethylene glycol (PEG) or polyvinylalcohol (PVA), polysaccharides like dextrin, 
dextran or hyaluronic acid , disaccharides like maltose and monosaccharides like 
galactose (Fig. 2A)[86,87]. These microneedles dissolve within minutes once inserted 
into the skin. Dissolving microneedles used for influenza vaccination are most often 




and a suitable matrix is poured (sometimes aided by centrifugation) into a mould 
where it solidifies to create the desired cast of a microneedle array. Solidification of 
the matrix can be the result of a photo-polymerization process or a drying step[58]. 
Since a certain force, velocity and sharpness are needed to penetrate the microneedles 
into the skin, the mechanical strength of the water dissolving matrix material used 
to encapsulate the vaccine is also important and should be well investigated when 
developing (dissolving) microneedles. 
In-vivo studies have been carried out using dissolving microneedles and the 
immunogenicity was compared to either coated microneedles or conventional 
parenteral routes. Sullivan et al. used dissolving PVP based microneedles 
encapsulating lyophilized WIV and compared the immunogenicity and protective 
efficacy to that in i.m. vaccinated mice (Table 1)[58]. Humoral as well as cellular 
immune responses and improved serological memory, strong enough to protect 
against lethal challenge were found after dissolvable microneedle vaccination. In 
comparison to i.m. route, reduced lung viral titers and enhanced cellular recall 
responses were determined after microneedle immunization. Moreover, dissolvable 
microneedles were found to have comparable humoral and superior induction of 
cellular responses when compared with coated microneedles[58]. Recently, Vassilieva 
et al. developed a gelatine based microneedle patch encapsulating different strains 
of WIV and found the induction of neutralizing antibody titers better (all strains) than 
after conventional i.m. immunization[72]. Further, antigen stability was retained after 
storage for three months at room temperature[72]. Also, a clinical study investigated 
the safety and efficacy of dissolving microneedles containing sodium hyaluronate, 
dextran 70, povidone and trivalent seasonal influenza subunit vaccine[17]. No severe 
local and systemic adverse events were observed, however, at the site of application 
the skin displayed local temporary erythema. Although the efficacy of the vaccine 
against the B strain was stronger than after s.c. immunization, immune responses 
against A/H1N1 and A/H3N2 were equally induced[17].
Intranasal and pulmonary dry powder influenza vaccine delivery
Targeting influenza vaccines to the mucosal sites in the airways might be advantageous 
because of the enormous surface area and extensively developed innate and adaptive 




enables the transport of antigens to the lymph nodes and the initiation of immune 
responses against the antigens[88]. The mucosal surface is a well-developed system 
consisting of nasal associated lymphoid tissue (NALT) in the upper respiratory tract, 
and inducible bronchus associated lymphoid tissue (iBALT) in the lower respiratory 
tract[89]. These lymphoid tissues play a major role in the stimulation and modulation 
of immune responses in the upper and lower respiratory tract[89]. Hence, in cases 
of respiratory infectious diseases such as influenza, the delivery of antigen at the 
natural portal of virus entry might reduce antigen dose and induce local (mucosal) 
immune responses.
Nasal dry powder influenza vaccine delivery
When targeting the intranasal area using dry powders, one should take into account 
several factors like particle size, density, and air velocity during administration. 
Particles bigger than 50 µm usually show reproducible intranasal deposition and do 
not follow the streamline direction of inhaled air; they thereby prevent deposition in 
the lung[90]. The high clearance rate of the nose might potentiate nasal  tolerance 
against influenza vaccination. This would make the use of mucoadhesives like 
chitosan or hypromellose necessary to increase the residence time of the vaccine 
(Fig. 2A). 
In a study conducted in rats by Huang et al. the nasal delivery of freeze dried and 
subsequently milled WIV (A/PR8 H1N1) formulations blended with mucoadhesive 
(chitosan), generated comparable systemic and better nasal antibody titers than were 
found after i.m. administration[76]. Moreover, the dry powder formulation remained 
completely stable (as determined by the hemagglutination assay) when stored at 
25°C/25% RH for 12 weeks, whereas the potency of the liquid formulation was 
reduced to 12.5%[76]. Several other mucoadhesives like sodium alginate (SA) or 
cellulose derivatives like CMC and HPMC were used by Garmise et al. in a similar 
way (Table 1)[77]. It was found that i.n. WIV (A/PR8 H1N1) formulations,  formulated 
with or without these mucoadhesives, elicited similar serum antibody titers and 
higher nasal IgA titers than formulations administered by i.m. route to rats. Also, 
the stability of the powder formulations was well preserved for 25°C/40% RH for 
12 weeks whereas liquid vaccine lost 70% of its stability under similar conditions 




The potential of in situ gelling nasal inserts as a delivery system for influenza  vaccine 
was investigated by Bertram et al [78]. The inserts were manufactured by freeze 
 drying hydrophilic polymer solutions containing influenza split vaccine (H1N1) with 
or without several adjuvants. Upon contact with the nasal mucosa, the hydrophilic 
polymeric matrix takes up water leading to gel formation after which the vaccine 
is released in a controlled manner. In-vivo studies in rats revealed that freeze dried 
influenza vaccine incorporated in xanthan gum with or without cationic lipid (CL) 
adjuvant, elicited serum IgG titers similar to those of pure i.n. liquid solution[78]. 
The authors hypothesized a probable interaction between oppositely charged xanthan 
gum and CL, which could inhibit antigen-adjuvant interaction to boost the immune 
response. The production of xanthan gum nasal inserts might be an interesting 
 alternative to enhance the stability of influenza antigen while maintaining an immune 
response similar in magnitude to that of liquid formulations. Vacuum dried chitosan 
nanospheres encapsulating WIV (A/New Caledonia H1N1) and adjuvants like CpG 
ODN or Quillaja saponins were also tested for their suitability as nasal particulate 
delivery system[12,79]. The structure of WIV was unaffected by encapsulation. The 
chitosan nanospheres encapsulated with influenza whole virus and CpG ODN 
 generated both local and systemic humoral and cellular immune responses in  rabbits, 
and induced higher levels of IgA than did liquid nasal and i.m. formulations[79]. 
Therefore, it can be concluded from the aforementioned studies that the influenza 
vaccine in a dry state not only enhances the stability of the antigen but also 
generates immune response comparable to that of liquid i.m. or i.n. formulations.
Pulmonary dry powder influenza vaccine delivery
Spherically shaped influenza vaccine powder particles, suitable for pulmonary delivery 
have been prepared by spray or spray freeze drying using saccharides like inulin 
and trehalose as stabilizers and bulking agents (Fig. 2A). To reach the central and 
peripheral airways particle size, particle density and particle shape play an important 
role. To do so effectively the aerodynamic particle size should be in the range of 
1–5 µm. The aerodynamic size or diameter of a particle takes into account the 
particle’s density and the shape of the particle (dynamic shape factor), and is defined 
as the diameter of a perfect spherical particle with a density of 1 g/cm3 having the 




with an aerodynamic size greater than 5 µm will show high deposition in the throat, 
upper and central airways while a large fraction of particles with an aerodynamic 
diameter smaller than 1 µm will be exhaled[91]. It is still not completely known 
which part of the lungs should be targeted for optimal pulmonary immunization 
against influenza. Studies conducted by Waldman et al. in the late sixties did show 
protective antibodies against influenza in children and adults without severe adverse 
reactions after pulmonary administration of liquid aerosolized inactivated influenza 
vaccine by nebulization[92,93]. Various in-vivo studies have shown that pulmonary 
immunization against influenza by dry powder delivery is a promising approach. 
Amorij et al. demonstrated with mice that pulmonary delivery of influenza subunit 
vaccine spray freeze dried in the presence of inulin (A/Panama H3N2) resulted in a 
better immune response than did i.m. liquid immunization (Table 1)[80]. Pulmonary 
powder delivery was able to elicit increased systemic humoral (IgG), mucosal (IgA 
and IgG) and cell mediated immune responses (IFN-g and IL-4) as compared to i.m. 
vaccination. Moreover, pulmonary powder immunization induced a balanced superior 
Th1/Th2 immune response as compared to the Th2 dominant response after i.m. 
injection. A Th1 or a balanced Th1/Th2 response is considered to be superior 
because it plays a key role in virus neutralization and provides a certain degree of 
cross-reactive immunity and thus results in better protection against infection[94,95]. 
The occurrence of high levels of IgG and IgA antibodies in the lungs and minor 
antibody titers in the nose was attributed to the migration of immune effector cells 
from the primary mucosal induction site (lungs) to the secondary distant mucosal site 
(nose)[80]. In a follow up study, Saluja et al. showed that the integrity of the antigen 
was best conserved after spray drying and spray freeze drying when formulated in 
phosphate buffer saline (PBS) and hepes buffer saline (HBS), respectively[24]. The 
stability of the dried antigen as determined by single radial immunodiffusion assay 
was preserved for 3 years at room temperature whereas the potency of the liquid 
vaccine was below detection limits after 3 years of storage at 4°C[24]. Long term 
immunogenic and physical stability of WIV at elevated storage temperatures was 
achieved after spray freeze drying them in the presence of suitable stabilizers[11]. 
Audouy et al. compared the virus protecting potential of two doses of WIV (A/PR8) 
spray freeze dried powders administered via the pulmonary route with a single 




viral challenge, the weight loss of the animals vaccinated with dry powders via the 
pulmonary route was significantly lower than the weight loss of the animals which 
were administered with liquid vaccine via the i.m. route. Moreover, powder treated 
animals had the largest reduction in lung virus titer[81]. 
Peeters et al. assessed the protective efficacy of unadjuvanted pulmonary delivered 
dry powder influenza vaccines against viral challenge in chickens[82]. It was 
found that the antibody levels induced by unadjuvanted dry powder WIV (H5N1) 
formulations were sufficient to fully protect chickens from morbidity and mortality 
after highly pathogenic avian influenza virus challenge (H5N1)[82]. In contrast to 
the results of Amorij et al [80], other studies with dry unadjuvanted WIV or subunit 
formulations showed that the latter elicited a Th2 dominated response, evidenced 
by the high IgG1 antibody titers, as compared to IgG2a antibody titers after 
pulmonary administration[11,81]. Besides a Th2 dominated response, low nasal IgA 
titers by pulmonary delivered dry powders also indicate the need for using suitable 
mucosal adjuvants. Hence, influenza vaccine formulations were adjuvanted with 
saponin adjuvant GP-0100 and the TLR ligands, monophosphoryl lipid A (MPLA), 
palmitoyl-3-cysteine-lysine-serine-4 (Pam3CSK4), and CpG ODN to increase the 
magnitude of the mucosal immune response and to direct the immune response 
towards the Th1 phenotype[83,84]. These adjuvants were selected because they have 
been shown to enhance systemic humoral responses after parenteral administration 
of influenza vaccines[96,97]. Besides this, they have also been used as mucosal 
adjuvants for influenza and tuberculosis antigens[98–100]. Dry powder pulmonary 
immunization of WIV (A/Hiroshima H3N2) adjuvanted with MPLA induced a higher 
production of superior Th1 type serum antibody titers (IgG2a) than did unadjuvanted 
formulations. Moreover, the dry MPLA adjuvanted influenza vaccine powders induced 
higher mucosal IgA and IgG antibody titers in both nose and lungs before and after 
challenge. Pulmonary immunization with WIV adjuvanted formulations was found to 
be as effective as standard subunit i.m. formulation in reducinglung virus titers after 
challenge (A/PR8). Hence, the co-administration of WIV with MPLA adjuvant could 
steer to a Th1 type immune response and be able to elicit potent mucosal antibody 
titers in the lungs[83]. Likewise, other TLR and saponin based adjuvants were also 
found to direct the immune response of pulmonary delivered dry powder WIV 
(A/California H1N1) formulations to either dominant Th1 type or balanced Th1/Th2 




was able to provide partial protection against heterologous virus challenge (A/PR8 
H1N1[84]. 
Besides being stable and immunogenic, a vaccine and an adjuvant should not induce 
undesirable side effects. Audouy et al. investigated the safety of pulmonary influenza 
vaccination[81]. Administration to mice of spray freeze dried WIV in the presence of 
inulin did induce mild transient cell influx but the inflammatory reactions subsided 
with time[81]. Also, pulmonary administration of the GP-100 formulation did not 
induce gross lung inflammation[84]. 
In conclusion, the dry influenza powders (adjuvanted/unadjuvanted) were stable 
and their delivery by pulmonary route was safe, effective and capable of protection 
against viral challenge.
Sublingual, buccal and gastrointestinal dry influenza vaccine delivery
Immunization via the oral route (mucosal areas of mouth and gastrointestinal tract) 
is a potentially attractive site to target for influenza vaccination. The mucosa of 
sublingual (s.l.) and buccal regions in the mouth contains DC and LC which are 
involved in the uptake, processing and presentation of the antigen to T-cells to 
induce an adaptive immune response[101]. Liquid influenza vaccination by the s.l. 
route has already been shown in various studies to induce systemic, mucosal and 
cellular immune responses in mice[102,103]. However, dry influenza vaccine delivery 
by s.l. or buccal routes has not yet been investigated in detail. Recently, Murugappan 
et al. incorporated lyophilized WIV into a tablet with a good crushing strength and 
a low disintegration time making it suitable for s.l. administration[18]. Moreover, 
the hemagglutinating capacity of the antigen was well preserved after freeze drying 
and tablet manufacture. However, the lack of dissolution of these tablets under the 
tongue in appropriate animal models like mice led to reconstitution of the powders 
to show the potential of s.l. administration[18]. McNeilly et al. targeted murine buccal 
mucosa with dried split influenza vaccine (Fluvax) coated on a Nanopatch and then 
compared the elicited immunogenicity to liquid formulations given i.m. or orally 
(gastrointestinal tract)[19]. The systemic IgG titers induced by Nanopatch buccally 
applied were comparable to those after i.m. administration and significantly higher 
than after gastrointestinal immunization. Furthermore, 4 out of 5 mice immunized 




whereas only 1 out of 5 animals immunized i.m. reached the minimum value of 
40 and no HAI activity was detected in gastrointestinal immunized mice. Hence, 
the buccal Nanopatch delivery of dry split influenza vaccine generated comparable 
and better immune responses than did the i.m. and oral routes, respectively[19]. The 
better immune responses generated by the buccal route were attributed to the uptake 
of antigen by oral mucosa rather than oral ingestion of the vaccine[19].
The ease of administration, patient compliance and the presence of gut associated 
lymphoid tissue (GALT) make oral vaccine for intestinal delivery an attractive 
administration route. However, the potential of the oral route for influenza vaccine 
delivery in the intestines is yet to be proven. Enormous challenges like acidic gastric 
pH, suitable oral adjuvants, oral tolerance, choice of which intestinal region to target, 
a suitable delivery system, delivery mechanism and the vaccine’s immunogenicity 
need to be dealt with so as to design a successful oral influenza vaccine formulation. 
Some progress has however, been made. Recently, an adenovirus based oral influenza 
vaccine enteric coated tablet (H1N1) was manufactured to investigate its safety and 
immunogenicity in healthy adults (Table 1)[20]. It was well tolerated and the majority 
of the adults reached HAI titers ≥ 40, whereas no seroconversion was found in the 
placebo group. In addition, a fourfold increase in the micro-neutralization titers for 
the vaccine group as compared to the control group was recorded. Hence, more than 
90% of the individuals had high humoral responses elicited by oral influenza vaccine 
delivery[20]. 
Dry influenza vaccine formulations for oral delivery are still at a very early stage 
of development. However, the stability and immunogenicity of influenza vaccines 
formulated in tablets or coated on Nanopatch and administered by oral, sublingual or 
buccal routes seem very promising and hold great potential for future developments 
in this field. 
Expert commentary 
Parenteral influenza vaccines have for more than eighty years now been considered 
to be the benchmark in influenza vaccination. However, the need for a cold chain, 
and often insufficient immune responses are the major disadvantages of currently 
available injectable influenza vaccines. The development of stable dry influenza 




possible and improving availability to the public. Drying an influenza vaccine under 
appropriate conditions and using suitable stabilizers would not only provide better 
stability of the antigen but also improve its efficacy when administered by a suitable 
route of interest like the skin or mucosal areas[56,79,80,19]. Fig. 2B gives a general 
overview of the advantages and disadvantages of dry influenza vaccination per route 
of administration. As shown by various preclinical and clinical studies, vaccinating 
the skin against influenza by microneedles or epidermal powder delivery results in a 
direct activation of the residing immune cells providing immune responses stronger 
or equal to those evoked by parenteral influenza vaccination[9,17,61,63]. However, 
A
B
Fig. 2 (A) Formulation excipients required for the production of dry, stable influenza vaccines 
per route of administration. (B) A general overview of advantages and disadvantages associated 
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the high costs of epidermal powder delivery by a device like the PowderJect limits 
its relevance for mass vaccination[104]. Other disadvantages of epidermal powder 
immunization are that it causes erythema, edema, petechiae, skin discoloration, 
and flaking of the skin[9] which could lead to reduced patient compliance. Therefore, 
application of coated non-dissolving microneedles is an attractive alternative as it is 
cheap, it can be self-administered and it does not cause the side effects related to 
ballistic administration. Despite the numerous advantages of the use of microneedles, 
antigen integrity during drying/storage remains a troublesome issue. It has been found 
that the presence of surfactant causes crystallization of stabilizing excipients and 
thus phase separation of vaccine coatings during drying or during long term storage 
by which the stabilizing effects of the excipients are lost[13,68]. Another disadvantage 
is the risk of needles being broken off and left in the skin during administration. The 
use of dissolving microneedles would be an attractive alternative to circumvent this 
problem. However, long term storage stability of the antigen in these microneedles 
has not been addressed thus far. In addition, the production and formulation of 
microneedles is labor intensive and challenging at a laboratory scale. New processes 
should be developed to efficiently produce these microneedles on an industrial scale. 
Furthermore, clinically relevant models are necessary to investigate the efficacy of 
microneedles for vaccination against influenza in humans. Recently, the group of 
Prausnitz has started a phase 1 clinical trial to investigate the immunogenicity, safety, 
reactogenicity and acceptability of an inactivated influenza vaccine delivered using a 
microneedle patch[105]. This could lead to new insights in the field of transtradermal 
influenza vaccination. 
While transdermal vaccination is a promising route, the initial transmission of 
influenza virus takes place via the airways through inhalation of small droplets from 
the air or by contaminated surfaces. Curbing the infection at the portal of entry would 
therefore seem to be a more logical approach. Intranasal and pulmonary influenza 
vaccination might be a more direct way to neutralize the virus by evoking a local 
immune response once it has entered the airways[106]. Intranasal immunization has 
been shown to provide broad immune responses and considerable protection[107,108]. 
However, dry powder intranasal influenza vaccines are still in a process of preclinical 
development. Low residence time, inefficient antigen uptake and the need for 
adjuvanted formulation with the subsequent risk of ciliotoxicity are the major hurdles 




adjuvants have been shown to redirect an antigen to the olfactory neuroepithelium, 
thereby inducing inflammatory responses in the nasal cavity[110]. Also, subsequent 
retrograde transport of the adjuvant into the olfactory bulb of the central nervous 
system has been indicated[110]. Mucoadhesives, particulate systems as well as safe, 
effective and tolerable adjuvanted formulations are being investigated to overcome 
these hurdles, thereby increasing the complexity of such formulations in terms of 
stability and immunogenicity[88,109]. Another factor to consider is which specific site 
to target within the nasal cavity. Anterior nasal mucosa do not include cilia; this 
reduces the risk of quick clearance of the administered vaccine, a risk that is greater 
in the highly ciliated posterior part of the nasal cavity[111]. However, targeting of 
the antigen to the posterior part might be desirable because it is close to the NALT. 
Nonetheless, the targeting areas within the upper and lower airways most likely to 
induce the best protective immune responses are still not yet completely known. 
Spray or spray freeze dried influenza vaccines administered by the pulmonary route 
have been shown to elicit local humoral and cellular immune responses providing 
comparable or better protection than parenteral administration[24,80,83]. Since the 
particle size and the delivery device play an important role in the deposition within the 
airways it is essential to characterize these components. The currently used method 
of administering a spray dried or spray freeze dried influenza vaccine to animals 
is by insufflation, using a device such as the Penn-Century dry powder insufflator. 
Insufflation by this device is based upon intubating the trachea of an animal like 
a rodent and then active dispersion of a dry powder using a certain volume of air 
(200–1000 µl). The limited volume of air that can be used for the dispersion of 
dry powder into rodents and high particle velocity generated during dispersion of 
the dry powder from the insufflator cause a high deposition within the upper part of 
the lungs[15,112]. This makes it complicated to investigate the relationship between 
the site of deposition and the protective immunity against influenza. New ways of 
pulmonary administration of dry powder influenza vaccines in a preclinical setting 
should therefore be investigated. A novel aerosol generator did show improved lung 
deposition in mice as compared to the dry powder insufflator from Penn-Century. 
This aerosol generator would seem to be a step towards improved devices for 
preclinical pulmonary animal studies[15]. The successful approach by Waldman et 
al. in the sixties and seventies already showed the effectiveness of liquid influenza 
vaccination after pulmonary administration via a nebulizer in humans[92,93]. However, 




formulation were not available at that time. To deliver a dry powder influenza vaccine 
via the pulmonary route a device should be disposable, cheap and easy to operate 
in case of pandemics without the need of healthcare personnel. Nowadays such 
devices are widely available[113], as for example the single-use disposable inhaler the 
Twincer®, with inulin stabilized solid influenza powder[114]. In-vitro experiments using 
a cascade impactor have shown that the dispersion of spray dried and spray freeze 
dried subunit influenza vaccine from the Twincer® is suitable for the administration 
to the human respiratory tract[24]. Although a single-use disposable inhaler like the 
Twincer® could be used in mass vaccination against influenza, it is not suitable for 
children up to 4 years old since they are not able to make the necessary inhalation 
manoeuvre[115]. It is also necessary to conduct clinical trials to investigate the safety, 
tolerability and efficacy of pulmonary delivered dry powder influenza vaccines.
Oral administration of influenza vaccines could be suitable for all age groups due 
to its ease of acceptance. APCs in the mucosal areas of the sublingual, buccal and 
gastrointestinal region can be targeted by tablets[20] or coated micro-projections 
like the Nanopatch[19], which show promising results. Viral vectors in tablets for 
gastrointestinal targeting can prevent gastric acid degradation. Coating strategies like 
the ColoPulse that utilize a delayed pulsatile release profile based on intestinal pH, 
could also be a potential way to deliver an antigen to the ileocolonic segment[116]. 
Still like the delivery of influenza vaccines into the airways, the optimal antigen 
deposition site within the gastrointestinal tract is still to be investigated.
Dry influenza vaccines show potential in terms of stability, efficacy, and their 
administration via non-parenteral routes is a convenient alternative to parenteral 
influenza vaccination, thus encouraging further developments. 
Five-year view
Dry influenza vaccines administered by non-parenteral routes are expected to draw 
more attention. Better pre-clinical models will be used to mimic human anatomy and 
physiology. More clinical trials will be conducted to examine the efficacy, safety and 
tolerability of newly developed dry influenza vaccines. These vaccines, delivered by 






l	 Parenteral vaccines are the cornerstone for mass influenza vaccination, yet the 
induction of broad humoral and cellular responses is limited.
l	 Liquid influenza vaccines require cold chain conditions.
l	 Properly dried influenza vaccines can be stored at room temperature with 
improved efficacy and enhanced patient acceptance by utilizing different routes 
of administration.
l	 The numerous APCs in the skin and mucosal areas of the airways, mouth and 
gastrointestinal tract make these areas excellent targets for influenza vaccination.
l	 Dry influenza vaccines should induce strong, and preferably cross-reactive 
immune responses.
l	 Dry influenza vaccines should be suitable for all age groups. 
l	 Dry influenza vaccination will result in immune responses equal to or better 
than those with conventional parenteral vaccination. 
l	 The number of clinical studies on dry influenza vaccination by different routes 
of administration is limited; the subject deserves more attention. 
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